PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 by Qingya Song, Zongliang Yu, Wenping Lu, Zhili Zhuo, Lei Chang, Heting Mei, Yongjia Cui, Dongni Zhang

Subjects: “…PD-1 inhibitors…”
Get full text

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1 by Suli Wang, Fujiao Nie, Qiuyue Yin, Haoyang Tian, Pizhang Gong, Jinhong Ju, Jiayi Liu, Pishan Yang, Chengzhe Yang

Subjects: Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

Subjects: Get full text

PD-1/PD-L1在膀胱癌患者外周血T细胞和肿瘤细胞表达 by 龙兆麟, 吴世皓, 华庆生, 张信基

Subjects: “…PD-1/PD-L1…”
Get full text

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors by Yanan Zhao, Di Wu, Quanjun Yao, Hang Yuan, Hongtao Hu, Hailiang Li

Subjects: Get full text

Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis by Zhiyong Wan, Meng Cui, Jia Yang, Dan Liao, Junliang Chen, Fanmin Li, Yin Xiang, Zhiwei Cui, Yang Yang

Subjects: “…PD-1+CD8+ T cells…”
Get full text

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives by Bujnak AC, File B, Tewari KS

Subjects: Get full text

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer by Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao

Subjects: Get full text

Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma by Xinan Wan, Mingxing Fang, Le Yuan, Hang Zhang, Dan Wang

Subjects: Get full text

PD‐1+CD8+ T Cell‐Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease by Jie Long, Si‐Yu Yang, Zhen‐Hua Bian, Hao‐Xian Zhu, Min Ma, Xiao‐Qing Wang, Liang Li, Weici Zhang, Ying Han, M. Eric Gershwin, Zhe‐Xiong Lian, Zhi‐Bin Zhao

Subjects: Get full text

GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis by Dušica Ristić, Thomas Bärnthaler, Eva Gruden, Melanie Kienzl, Laura Danner, Karolina Herceg, Arailym Sarsembayeva, Julia Kargl, Rudolf Schicho

Subjects: Get full text

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer by Lijuan Chen, Lijuan Chen, Pengju Wang, Carmela Di Gioia, Ming Yuan, Zhe Zhang, Jinxin Miao, Wenli Yan, Guanghao Zhao, Yangyang Jia, Na Wang, Zhongxian Zhang, Haoran Guo, Giulia Marelli, Louisa Chard Dunmall, Nicholas R. Lemoine, Nicholas R. Lemoine, Yaohe Wang, Yaohe Wang

Subjects: Get full text

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1... by Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

Subjects: Get full text

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade by Junjie Li, Yuandong Luo, Quanlan Fu, Shuxian Tang, Pingping Zhang, Ian H. Frazer, Xiaosong Liu, Tianfang Wang, Guoying Ni

Subjects: Get full text

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer by Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

Subjects: “…PD-1 inhibitors…”
Get full text

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer by Lulu Zhang, Lulu Zhang, Xiyuan Guo, Xiyuan Guo, Xiaoke Sun, Jue Liao, Qin Liu, Yingchun Ye, Zhihui Yang, Ratchada Cressey, Qing He, Qing Yuan, Qing Yuan

Subjects: Get full text

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

Subjects: “…PD-1…”
Get full text

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budi... by Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

Subjects: Get full text

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter P... by Jiamin Yu, Li Yin, Wenjie Guo, Qiang Wang, Juying Liu, Lansheng Zhang, Hongxun Ye, Jianhong Xia, Youyou Xia, Jianfeng Wu, Wanwei Wang, Yanguang Yang, Dan Zong, Xia He, Lijun Wang, Hong Jiang

Subjects: Get full text

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report by Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Zhiguo Luo, Ming Luo

Subjects: Get full text